Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07088926 | A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization | PHASE2 | RECRUITING | 435 | — | — | Nov 6, 2025 | Jun 14, 2028 | Jun 3, 2026 | 185 | United States, Argentina +23 |
To evaluate the effect of IV AZD0292 compared to placebo on the rate of moderate-to-severe pulmonary exacerbations in participants with NCFBE and chronic colonization with PsA.
| Arm | Type | Description |
|---|---|---|
| High-dose | EXPERIMENTAL | High-Dose AZD0292 administered starting on Day 1, subsequent administrations per schedule of assessments. |
| Low-dose | EXPERIMENTAL | Low-dose AZD0292 administered starting on Day 1, subsequent administrations per schedule of assessments. |
| Placebo | PLACEBO_COMPARATOR | Placebo administered starting on Day 1, subsequent administrations per schedule of assessments. |
| Name | Type | Description |
|---|---|---|
| AZD0292 | BIOLOGICAL | AZD0292 high-dose or low-dose administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments. |
| Placebo | OTHER | Placebo administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments. |
Inclusion Criteria: 1. Participant must be ≥ 12 years of age at the time of signing the informed consent/assent 2. Weight ≥ 35 kg 3. Bronchiectasis diagnosed by a physician and confirmed by CT demonstrating abnormal bronchial dilation in ≥ 1 lobe. Note: A historical CT scan within the past 5 years ...